Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, explains how he works closely with patients and study sites in SURPASS-CVOT to avoid weight loss drug discontinuation ...

SURPASS-CVOT (NCT04255433) includes 12,500 participants with type 2 diabetes and atherosclerotic cardiovascular disease from 30 countries.

In an interview, Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, described the patient characteristics in the SURPASS-CVOT trial; patients had type 2 diabetes, a BMI ...

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D ...

Eli Lilly and Company (NYSE: LLY) Tirzepatide SURPASS Program Overview Conference Call November 20, 2020 11:00 AM ET Company Participants Kevin Hern - VP of IR Mike Mason - President of Lilly ...

The first patient dose has been delivered in the phase III study (SURPASS-CVOT) to evaluate if tirzepatide can reduce the risk of cardiovascular events in patients with type II diabetes and ...

Amgen’s Repatha CVOT Results Are Potential Game-Changer for Lipid-Lowering Treatment Seen as market catalyst for Amgen and other developers of competing lipid-lowering therapies: ...

The SURPASS-CVOT trial will assess both non-inferiority and superiority of tirzepatide in a head-to-head trial against Trulicity (dulaglutide) 1.5 mg, which is already proven to significantly ...